OncoSenX raises $3M to advance non-viral, gene-delivery cancer therapeutics targeting solid tumors
Seattle startup OncoSenX raised $3 million to advance a non-viral, lipid nanoparticle gene-delivery platform that aims to selectively kill solid tumor cells based on their genetic mutations, and plans to use the funding to accelerate preclinical work toward Phase 1 trials.